Related Experiment Video

Updated: Apr 29, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K

Treatment of chronic phase chronic myeloid leukemia with imatinib

Prasanth Ganesan1, Rejiv Rajendranath, Vignesh Kandakumar

  • 1Department of Medical Oncology, Cancer Institute (WIA) Sardar Patel, Road Adyar, Chennai, 600020, Tamil Nadu, India, prasanth.ganesan@cancerinstitutewia.org.

Indian Journal of Pediatrics
|May 30, 2014
PubMed

Insights

Imatinib is an effective and well-tolerated first-line therapy for pediatric Chronic Myeloid Leukemia (CML). This treatment shows promising outcomes, with high response rates and good progression-free survival (PFS) and overall survival (OS) in children with CML.

Area of Science:

  • Pediatric Hematology Oncology
  • Pharmacological Treatment of Leukemia

Background:

  • Chronic Myeloid Leukemia (CML) in children requires effective and well-tolerated treatment options.
  • Upfront imatinib therapy has emerged as a significant advancement in CML management.

Purpose of the Study:

  • To evaluate the outcomes of pediatric patients with Chronic Myeloid Leukemia in chronic phase (CML-CP) treated with upfront imatinib.
  • To quantify treatment response rates, progression-free survival (PFS), and overall survival (OS) in this cohort.

Main Methods:

  • Retrospective analysis of 31 pediatric patients (≤18 years) diagnosed with CML-CP treated with imatinib (260-300 mg/m²) between 2003-2008.
  • Assessment of hematological, cytogenetic, and molecular responses, alongside PFS and OS.

Main Results:

  • 97% of patients achieved complete hematological response within 2 months.
  • At 2 years, major and complete cytogenetic response rates were 82% and 70%, respectively.
  • Five-year PFS and OS were 68% and 76%, with no serious toxicities reported.

Conclusions:

  • Upfront imatinib is a safe and effective first-line treatment for pediatric CML-CP, yielding outcomes comparable to Western studies.
  • Further improvements in outcomes may be achieved through access to second-line agents and stem cell transplantation.
Abstract

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
749
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K